High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas
Authors Si D, Yin F, Peng J, Zhang G
Received 4 October 2019
Accepted for publication 15 January 2020
Published 3 February 2020 Volume 2020:12 Pages 769—775
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Antonella D'Anneo
Daolin Si,1 Fei Yin,1 Jing Peng,1 Guangying Zhang2
1Department of Pediatric Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, People’s Republic of China; 2Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, People’s Republic of China
Correspondence: Guangying Zhang
Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, Hunan Province 410008, People’s Republic of China
Tel +86-731- 89753043
Fax +86-731- 89753332
Purpose: Glioblastoma multiforme (GBM) is the most common of the malignant and invasive gliomas. High grade glioma is prone to relapse and has a poor prognosis. However, there is a big difference in terms of survival time with the same grade glioma. Cluster of differentiation 44 (CD44) is an indicator of cancer stem cells with abnormal expression in many malignant tumors, however the expression in GBM is unknown.
Methods: Tissue specimens were collected from 62 GBM patients to investigate CD44 expression and their prognosis was followed-up. Chi-square test was used to identify the association between CD44 staining and clinical characteristics of the patients. Kaplan-Meier analysis was performed to draw survival curves and Cox regression analysis to confirm the independent prognostic factors of GBM patients.
Results: In total, 38.7% (24/62) of the patients had high CD44 staining. The median survival times were 3.5 months and 18.5 months for high and low expressions of CD44, respectively. Kaplan-Meier analysis revealed that tumor location, the extent of tumor resection, adjuvant chemotherapy, and CD44 expression were related to overall survival time of GBM patients (P<0.05). Multivariate analysis showed that non-usage of adjuvant chemotherapy (HR=4.097, 95% CI=1.489– 11.277, P=0.006) and CD44 overexpression (HR=3.216, 95% CI=1.452– 7.125, P=0.004) were independent unfavorable prognostic factors for GBM patients.
Conclusion: The results demonstrate that high expression of CD44 acts as a poor prognosis indicator in GBM patients.
Keywords: glioblastoma, CD44, immunohistochemistry, survival times
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]